Get started
Author

Laura Beatriz Prato

Observed names: Laura B. Prato, Laura Prato, Laura Pratto, Prato, Laura, Prato, Laura Beatriz
ORCID: 0000-0001-7767-4554
Observed ORCID: 0000-0001-7767-4554
OpenAlex ID: A5112966987
The impact of quality control in RNA-seq experiments
2016 · Gabriela A Merino, Cristóbal Fresno, et al. · Journal of Physics Conference Series · 25
PDF
Early Detection of Chronic Asymptomatic Chagas Infection
2018 · Ezequiel de la Rosa, Patricia Paglini-Oliva, et al. · Medical Science Monitor · 24
Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis
2023 · Guadalupe Nibeyro, Veronica Baronetto, et al. · Frontiers in Immunology · 23
PDF
Novel evaluation approach for molecular signature-based deconvolution methods
2023 · Agustín Nava, Daniela Alves da Quinta, et al. · Journal of Biomedical Informatics · 9
Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature
2020 · Darío Rocha, Iris A. García, et al. · Cells · 8
PDF
MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicity
2022 · Guadalupe Nibeyro, Romina Girotti, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Appropriate Sample Size for Standardization Parameters Estimation Reduces Misdiagnoses of Molecular-Based Risk Predictors in Breast Cancer
2017 · Aldana González-Montoro, Laura Prato, et al. · Medical Science and Technology · 3
Non-Invasive Chronic Asymptomatic Chagas Disease Screening Through High-Resolution Electrocardiography (ECG)
2017 · Ezequiel de la Rosa, Patricia Paglini-Oliva, et al. · Medical Science and Technology · 2
Herramientas de la Web 2.0 aplicadas a la educación
2013 · Hugo Emilio Traverso, Laura Beatriz Prato, et al. · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · 2
PDF
Figure 4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Supporting_Information from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 2 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 6 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table 1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table S1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Data from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S2 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al. · Cancer Research Communications
Positive control as a validation strategy in multiblock analysis: an implementation to a breast cancer subtypes study
2020 · Darío Rocha, Aldana González Montoro, et al. · Repositorio Digital de la UNC (National University of Cordoba)
PDF
Generación Y Fortalecimiento De Vínculos Interuniversitarios Destinados Al Desarrollo De Aplicaciones Informáticas Y Estadísticas En Biociencias
2016 · Laura Beatriz Prato, Elmer Fernández · Americanae (AECID Library)
Works count: 33
Citation count: 102
H-index: 6
I10-index: 3
Year
Topic
Type